S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.74 (+0.57%)
AAPL   180.52 (-0.50%)
MSFT   408.56 (+0.21%)
META   487.77 (+0.77%)
GOOGL   136.84 (+0.34%)
AMZN   174.91 (+1.01%)
TSLA   200.12 (-0.95%)
NVDA   792.82 (+2.08%)
NIO   5.66 (+4.24%)
AMD   187.42 (+6.16%)
BABA   74.20 (-0.52%)
T   17.03 (+0.41%)
F   12.45 (+1.22%)
MU   89.78 (+0.08%)
CGC   3.32 (-1.19%)
GE   156.08 (+0.30%)
DIS   111.40 (+0.54%)
AMC   4.44 (-11.02%)
PFE   26.88 (-0.59%)
PYPL   60.56 (+0.51%)
XOM   104.62 (+0.29%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.74 (+0.57%)
AAPL   180.52 (-0.50%)
MSFT   408.56 (+0.21%)
META   487.77 (+0.77%)
GOOGL   136.84 (+0.34%)
AMZN   174.91 (+1.01%)
TSLA   200.12 (-0.95%)
NVDA   792.82 (+2.08%)
NIO   5.66 (+4.24%)
AMD   187.42 (+6.16%)
BABA   74.20 (-0.52%)
T   17.03 (+0.41%)
F   12.45 (+1.22%)
MU   89.78 (+0.08%)
CGC   3.32 (-1.19%)
GE   156.08 (+0.30%)
DIS   111.40 (+0.54%)
AMC   4.44 (-11.02%)
PFE   26.88 (-0.59%)
PYPL   60.56 (+0.51%)
XOM   104.62 (+0.29%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.74 (+0.57%)
AAPL   180.52 (-0.50%)
MSFT   408.56 (+0.21%)
META   487.77 (+0.77%)
GOOGL   136.84 (+0.34%)
AMZN   174.91 (+1.01%)
TSLA   200.12 (-0.95%)
NVDA   792.82 (+2.08%)
NIO   5.66 (+4.24%)
AMD   187.42 (+6.16%)
BABA   74.20 (-0.52%)
T   17.03 (+0.41%)
F   12.45 (+1.22%)
MU   89.78 (+0.08%)
CGC   3.32 (-1.19%)
GE   156.08 (+0.30%)
DIS   111.40 (+0.54%)
AMC   4.44 (-11.02%)
PFE   26.88 (-0.59%)
PYPL   60.56 (+0.51%)
XOM   104.62 (+0.29%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.74 (+0.57%)
AAPL   180.52 (-0.50%)
MSFT   408.56 (+0.21%)
META   487.77 (+0.77%)
GOOGL   136.84 (+0.34%)
AMZN   174.91 (+1.01%)
TSLA   200.12 (-0.95%)
NVDA   792.82 (+2.08%)
NIO   5.66 (+4.24%)
AMD   187.42 (+6.16%)
BABA   74.20 (-0.52%)
T   17.03 (+0.41%)
F   12.45 (+1.22%)
MU   89.78 (+0.08%)
CGC   3.32 (-1.19%)
GE   156.08 (+0.30%)
DIS   111.40 (+0.54%)
AMC   4.44 (-11.02%)
PFE   26.88 (-0.59%)
PYPL   60.56 (+0.51%)
XOM   104.62 (+0.29%)
NASDAQ:ARTLW

Artelo Biosciences (ARTLW) Stock Price, News & Analysis

$0.01
0.00 (0.00%)
(As of 02/28/2024 ET)
Today's Range
$0.0143
$0.0143
50-Day Range
$0.01
$0.04
52-Week Range
$0.01
$0.21
Volume
21 shs
Average Volume
7,011 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ARTLW stock logo

About Artelo Biosciences Stock (NASDAQ:ARTLW)

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

ARTLW Stock Price History

ARTLW Stock News Headlines

Detecting Cancer in Mere Seconds: Early Investment Opportunity
A revolutionary cancer diagnostic tool is likely to come to fruition with anticipated FDA approval expected in just months. With the ability to detect cancer's "molecular fingerprint" in just seconds, it also offers far superior accuracy to current detection methods and reduces the need for invasive biopsies.
Detecting Cancer in Mere Seconds: Early Investment Opportunity
A revolutionary cancer diagnostic tool is likely to come to fruition with anticipated FDA approval expected in just months. With the ability to detect cancer's "molecular fingerprint" in just seconds, it also offers far superior accuracy to current detection methods and reduces the need for invasive biopsies.
Artelo Biosciences, Inc. (ARTLW)
eFFECTOR Therapeutics, Inc. (EFTRW)
See More Headlines
Receive ARTLW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ARTLW
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Gregory D. Gorgas M.B.A. (Age 61)
    President, CEO, CFO, Treasurer, Secretary & Director
    Comp: $654.83k
  • Dr. Andrew Yates Ph.D.
    Senior VP & Chief Scientific Officer
  • Dr. Steven D. Reich (Age 78)
    Chief Medical Officer
  • Mr. Jason H. Baybutt (Age 52)
    Senior Vice President of Finance














ARTLW Stock Analysis - Frequently Asked Questions

How have ARTLW shares performed in 2024?

Artelo Biosciences' stock was trading at $0.0399 on January 1st, 2024. Since then, ARTLW stock has decreased by 64.2% and is now trading at $0.0143.
View the best growth stocks for 2024 here
.

How do I buy shares of Artelo Biosciences?

Shares of ARTLW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARTLW) was last updated on 2/29/2024 by MarketBeat.com Staff